Department of Oncology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Department of Oncology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Am J Med Sci. 2022 Apr;363(4):342-350. doi: 10.1016/j.amjms.2021.09.015. Epub 2021 Dec 24.
The purpose of this study was to evaluate the efficacy and safety of recombinant human endostatin (rh-ES) combined with chemotherapy in advanced gastrointestinal tumors in China.
A literature search was performed in PubMed, Medline, Springer, Elsevier Science Direct, Weipu, Wanfang, and China National Knowledge Infrastructure (CNKI), with the last report through September 2019. The included research was scored using a modified Jadad scale, and a meta-analysis was performed using RevMan 5.3 software.
Twenty articles including 905 participants (experimental group [rh-ES combined with chemotherapy] 459; control group [chemotherapy alone] 446) were considered. The total effective rate for the experimental group in advanced gastrointestinal tumors was higher than that of the control group (P<0.05). No significant difference in adverse reactions was seen between the two groups (P>0.05).
The short-term efficacy of rh-ES combined with chemotherapy for advanced gastrointestinal tumors was better, with fewer adverse reactions.
本研究旨在评估重组人血管内皮抑制素（rh-ES）联合化疗治疗中国晚期胃肠道肿瘤的疗效和安全性。
检索 PubMed、Medline、Springer、Elsevier Science Direct、维普、万方和中国知网（CNKI）中的文献，检索截至 2019 年 9 月。采用改良 Jadad 量表对纳入的研究进行评分，并使用 RevMan 5.3 软件进行荟萃分析。
共纳入 20 篇文献，包括 905 例患者（实验组[rh-ES 联合化疗]459 例，对照组[单纯化疗]446 例）。实验组晚期胃肠道肿瘤的总有效率高于对照组（P<0.05）。两组不良反应发生率无显著差异（P>0.05）。
rh-ES 联合化疗治疗晚期胃肠道肿瘤的近期疗效较好，不良反应较少。
